Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record

China sets a world record sustaining fusion plasma for 17 minutes

By / / Good News For Humankind

China fusion plasma record: Scientists have sustained superheated fusion plasma for more than 17 minutes inside an experimental reactor, the longest confinement time ever recorded at that temperature. China’s EAST tokamak held plasma at 100 million degrees Celsius for 1,066 seconds, more than doubling its own previous record. This matters because sustained plasma confinement is one of fusion energy’s hardest engineering challenges, and solving it brings humanity closer to clean, near-limitless power. Fusion produces no carbon emissions and uses hydrogen isotopes from seawater as fuel, making this milestone genuinely significant for the global energy future.

Industrial turbine machinery in a modern power facility for an article about supercritical CO2 power generation — 13 words.

China connects the world’s first commercial supercritical CO2 power generator to the grid

By / / Good News For Humankind

Supercritical CO2 power generation has reached a historic milestone as China’s Harbin Electric Corporation becomes the first in the world to operate a commercial-scale turbine using supercritical carbon dioxide — and connect it to a live national grid. The technology replaces conventional steam with pressurized CO2, achieving thermal efficiencies above 50% compared to roughly 40% for the best modern steam plants. Beyond efficiency, the turbines are dramatically more compact and work across multiple energy sources, including solar, nuclear, and industrial waste heat. China’s success gives the global engineering community proof that this long-pursued technology can actually work at scale, likely accelerating development timelines worldwide.

A researcher working with cells in a laboratory for an article about base-edited T-cells leukemia treatment

Base-edited T-cells clear incurable leukemia in landmark U.K. trial

By / / Good News For Humankind

Base-edited T-cells have pushed an otherwise incurable blood cancer into remission for the first time in medical history, marking a landmark moment in cancer treatment. Scientists at Great Ormond Street Hospital and University College London developed BE-CAR7, a therapy using donor T-cells precisely engineered through base editing to target T-cell acute lymphoblastic leukemia without attacking healthy tissue. The treatment achieved remission in the majority of trial participants who had already exhausted every conventional option. Unlike standard CAR-T therapies, BE-CAR7 can be batch-manufactured and deployed within days, making cutting-edge immunotherapy faster, potentially cheaper, and more widely accessible.

A patient breathing into a medical device for an article about pancreatic cancer breath test

U.K. breath test for pancreatic cancer could transform early detection

By / / Good News For Humankind

Pancreatic cancer breath test developed by Imperial College London researchers could transform early detection of one of medicine’s deadliest diseases. Scientists identified specific volatile organic compounds in exhaled breath that signal early-stage pancreatic cancer, validated across more than 700 samples. The NHS has now launched a trial at roughly 40 hospital sites across England, Wales, and Scotland, targeting 6,000 patients, with results reaching doctors within three days. Since over 80% of cases are currently diagnosed after the cancer has spread, this fast, portable, low-cost test could shift outcomes from palliative to curative for thousands of patients annually.

Colorized microscopy image of neurons and plaques for an article about Alzheimer's nanoparticle treatment

A single injection reversed Alzheimer’s symptoms in mice, and researchers say humans could be next

By / / Good News For Humankind

Alzheimer’s nanoparticle treatment developed by scientists in Spain and China reversed disease symptoms in mice with a single injection, according to a study published in Nature Nanotechnology. Rather than targeting amyloid-beta plaques directly, the engineered nanoparticles crossed the damaged blood-brain barrier and restored the brain’s own waste-clearance system. Within one hour, researchers recorded a sharp drop in toxic protein levels, with memory function fully restored and effects lasting the equivalent of decades in human terms. While mouse results don’t guarantee human outcomes, the mechanism targeting barrier function over individual markers may prove more durable than previous approaches.

A neuroscientist reviewing brain scan imagery for an article about Huntington's disease gene therapy

U.K. scientists slow Huntington’s disease progression for the first time

By / / Good News For Humankind

Huntington’s disease gene therapy has achieved what researchers once considered impossible, with a single surgical injection slowing overall disease progression by 75% and functional decline by 60% in a University College London clinical trial. The experimental treatment, AMT-130, permanently reprograms neurons to stop producing the toxic protein responsible for destroying brain cells in this fatal inherited disorder. For the roughly 41,000 Americans living with Huntington’s and 200,000 more at genetic risk, the word “stable” now carries real clinical meaning. Beyond one disease, the gene-silencing techniques validated here are accelerating research into Alzheimer’s, Parkinson’s, and other neurological conditions affecting tens of millions worldwide.

Aerial view of a coastal industrial facility at dusk for an article about osmotic power plant technology in Fukuoka Japan

Japan switches on its first osmotic power plant in Fukuoka

By / / Good News For Humankind

Osmotic power has moved from laboratory concept to working reality with the opening of Japan’s first salinity gradient energy facility in Fukuoka. The plant harnesses the natural pressure difference between fresh water and concentrated brine waste from an adjacent desalination plant, generating clean electricity around the clock without fuel or weather dependence. Estimated to produce enough power for roughly 220 households annually, it is only the second facility of its kind in the world built for continuous operation. Its significance lies in the blueprint it offers: osmotic plants can attach to existing desalination infrastructure worldwide, turning a disposal problem into a steady power source.

A neuroscientist reviewing brain activity data on a monitor for an article about epilepsy drug RAP-219

New epilepsy drug cuts seizures by nearly 80% in mid-stage trial

By / / Good News For Humankind

Epilepsy drug RAP-219 has shown striking results in a mid-stage clinical trial, reducing seizures by a median of 77.8% in adults whose epilepsy had not responded to existing medications. Developed by Rapport Therapeutics, the drug works by precisely targeting overactive brain regions rather than broadly suppressing electrical activity across the whole brain. Nearly one in four participants became completely seizure-free during the eight-week study. The trial’s use of implanted neurostimulation devices provided objective, real-time brain data that strengthens confidence in the findings. Phase 3 trials are expected to begin in 2026.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

FDA approves twice-yearly lenacapavir HIV prevention shot with 99.9% effectiveness

By / / Good News For Humankind

Lenacapavir HIV prevention has reached a landmark moment: the FDA has approved the twice-yearly injectable drug — brand name Yeztugo — as the first long-acting PrEP option in history. Clinical trials showed it stopped transmission in more than 99.9% of participants, outperforming daily oral PrEP across tens of thousands of people. The breakthrough matters because adherence to daily medication has always been the weak point in HIV prevention, particularly in high-burden communities facing stigma and limited clinic access. Gilead has also signed royalty-free licensing agreements to supply affordable versions to 120 countries, prioritizing sub-Saharan Africa, Southeast Asia, and the Caribbean.

A healthcare worker caring for a newborn in a clinical setting for an article about newborn malaria treatment

World’s first malaria treatment approved for newborn babies

By / / Good News For Humankind

Newborn malaria treatment reached a historic milestone as regulators approved Coartem Baby, the first antimalarial drug designed specifically for infants weighing under 5 kilograms. Developed through a partnership between Novartis and the non-profit Medicines for Malaria Venture, the dissolvable, cherry-flavored medication fills a gap that persisted for decades, leaving the most fragile newborns without a safe, approved option. Approval has been fast-tracked across eight African countries where need is greatest, with Novartis committing to largely not-for-profit pricing. For the youngest infants born into high-transmission environments, this changes everything.